Skip to main content

Advertisement

SpringerLink
Log in

Strategies for molecular expression profiling in bladder cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Carcinoma of the urinary bladder involves alterations in multiple cellular pathways that dictate the pathology of the disease and clinical outcome of the patient. This includes alterations in regulation of the cell cycle, apoptotic mechanisms, signal transduction and tumor angiogenesis. Interrogation of alterations in multiple molecules associated with these pathways is leading to the development of biomarker panels that are capable of predicting an individual patient’s outcome or response to specific treatments. With respect to gene expression profiling, two broad approaches may be identified: a global approach and a pathway-specific approach. The global approach involves a high-throughput effort to profile the entire genome, while the pathway-specific approach quantifies select genes across several pathways. While the former has a high potential for discovery of novel signatures, the latter is important in generating reproducible and concise panels that have the potential for rapid clinical implementation. A combination of both these approaches is needed for the identification and validation of robust marker panels of potential clinical importance in bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Heney, N. M. (1992). Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urologic Clinics of North America, 19(3), 429–433.

    CAS  PubMed  Google Scholar 

  2. Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA A Cancer Journal for Clinicians, 55(2), 74–108.

    Article  PubMed  Google Scholar 

  3. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics. CA A Cancer Journal for Clinicians, 59(4), 225–249.

    Article  PubMed  Google Scholar 

  4. Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J., & Stein, J. P. (2008). Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Reviews in Urology, 10(1), 31–43.

    PubMed  Google Scholar 

  5. Mitra, A. P., Datar, R. H., & Cote, R. J. (2006). Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. Journal of Clinical Oncology, 24(35), 5552–5564.

    Article  CAS  PubMed  Google Scholar 

  6. Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A. C., Boyd, S., et al. (2001). Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Journal of Clinical Oncology, 19(3), 666–675.

    CAS  PubMed  Google Scholar 

  7. Mitra, A. P., Lin, H., Datar, R. H., & Cote, R. J. (2006). Molecular biology of bladder cancer: prognostic and clinical implications. Clinical Genitourinary Cancer, 5(1), 67–77.

    Article  CAS  PubMed  Google Scholar 

  8. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., et al. (1994). Accumulation of nuclear p53 and tumor progression in bladder cancer. New England Journal of Medicine, 331(19), 1259–1264.

    Article  CAS  PubMed  Google Scholar 

  9. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., et al. (1993). Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. Journal of the National Cancer Institute, 85(1), 53–59.

    Article  CAS  PubMed  Google Scholar 

  10. Serth, J., Kuczyk, M. A., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K., et al. (1995). p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. British Journal of Cancer, 71(1), 201–205.

    CAS  PubMed  Google Scholar 

  11. George, B., Datar, R. H., Wu, L., Cai, J., Patten, N., Beil, S. J., et al. (2007). p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. Journal of Clinical Oncology, 25(34), 5352–5358.

    Article  CAS  PubMed  Google Scholar 

  12. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. (1997). p53 and treatment of bladder cancer. Nature, 385(6612), 123–125.

    Article  CAS  PubMed  Google Scholar 

  13. Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996). Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381(6584), 713–716.

    Article  CAS  PubMed  Google Scholar 

  14. Mitra, A. P., Birkhahn, M., & Cote, R. J. (2007). p53 and retinoblastoma pathways in bladder cancer. World Journal of Urology, 25(6), 563–571.

    Article  CAS  PubMed  Google Scholar 

  15. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., et al. (1998). Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. Journal of the National Cancer Institute, 90(14), 1072–1079.

    Article  CAS  PubMed  Google Scholar 

  16. Mitra, A. P., Datar, R. H., & Cote, R. J. (2005). Molecular staging of bladder cancer. BJU International, 96(1), 7–12.

    Article  CAS  PubMed  Google Scholar 

  17. Simon, R., Struckmann, K., Schraml, P., Wagner, U., Forster, T., Moch, H., et al. (2002). Amplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene, 21(16), 2476–2483.

    Article  CAS  PubMed  Google Scholar 

  18. Sanchez-Carbayo, M., Socci, N. D., Kirchoff, T., Erill, N., Offit, K., Bochner, B. H., et al. (2007). A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clinical Cancer Research, 13(11), 3215–3220.

    Article  CAS  PubMed  Google Scholar 

  19. Mitra, A. P., & Cote, R. J. (2009). Molecular pathogenesis and diagnostics of bladder cancer. Annual Review of Pathology, 4, 251–285.

    Article  CAS  PubMed  Google Scholar 

  20. Miyamoto, H., Shuin, T., Torigoe, S., Iwasaki, Y., & Kubota, Y. (1995). Retinoblastoma gene mutations in primary human bladder cancer. British Journal of Cancer, 71(4), 831–835.

    CAS  PubMed  Google Scholar 

  21. Cote, R. J., Dunn, M. D., Chatterjee, S. J., Stein, J. P., Shi, S. R., Tran, Q. C., et al. (1998). Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Research, 58(6), 1090–1094.

    CAS  PubMed  Google Scholar 

  22. Chatterjee, S. J., George, B., Goebell, P. J., Alavi-Tafreshi, M., Shi, S. R., Fung, Y. K., et al. (2004). Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. Journal of Pathology, 203(3), 762–770.

    Article  CAS  PubMed  Google Scholar 

  23. Lipponen, P. K., & Aaltomaa, S. (1994). Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. Journal of Pathology, 173(4), 333–339.

    Article  CAS  PubMed  Google Scholar 

  24. Perabo, F. G., Kamp, S., Schmidt, D., Lindner, H., Steiner, G., Mattes, R. H., et al. (2001). Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. British Journal of Cancer, 84(10), 1330–1338.

    Article  CAS  PubMed  Google Scholar 

  25. Yamana, K., Bilim, V., Hara, N., Kasahara, T., Itoi, T., Maruyama, R., et al. (2005). Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. British Journal of Cancer, 93(5), 544–551.

    Article  CAS  PubMed  Google Scholar 

  26. Wolf, H. K., Stober, C., Hohenfellner, R., & Leissner, J. (2001). Tumour Biology, 22(5), 328–336.

    Article  CAS  PubMed  Google Scholar 

  27. Gonzalez-Campora, R., Davalos-Casanova, G., Beato-Moreno, A., Garcia-Escudero, A., Pareja Megia, M. J., Montironi, R., et al. (2007). BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Letters, 250(2), 292–299.

    Article  CAS  PubMed  Google Scholar 

  28. Maluf, F. C., Cordon-Cardo, C., Verbel, D. A., Satagopan, J. M., Boyle, M. G., Herr, H., et al. (2006). Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Annals of Oncology, 17(11), 1677–1686.

    Article  CAS  PubMed  Google Scholar 

  29. Fitzgerald, J. M., Ramchurren, N., Rieger, K., Levesque, P., Silverman, M., Libertino, J. A., et al. (1995). Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. Journal of the National Cancer Institute, 87(2), 129–133.

    Article  CAS  PubMed  Google Scholar 

  30. Birkhahn, M., Mitra, A. P., Williams, A. J., Lam, G., Ye, W., Datar, R. H., et al. (2010). Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. European Urology, 57(1), 12–20.

    Article  Google Scholar 

  31. Xia, G., Kumar, S. R., Hawes, D., Cai, J., Hassanieh, L., Groshen, S., et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Journal of Urology, 175(4), 1245–1252.

    Article  CAS  PubMed  Google Scholar 

  32. Mitra, A. P., Almal, A. A., George, B., Fry, D. W., Lenehan, P. F., Pagliarulo, V., et al. (2006). The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer, 6, 159.

    Article  PubMed  Google Scholar 

  33. Stephanou, A., Brar, B. K., Knight, R. A., & Latchman, D. S. (2000). Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death and Differentiation, 7(3), 329–330.

    Article  CAS  PubMed  Google Scholar 

  34. Mitra, A. P., Pagliarulo, V., Yang, D., Waldman, F. M., Datar, R. H., Skinner, D. G., et al. (2009). Generation of a concise gene panel for outcome prediction in urinary bladder cancer. Journal of Clinical Oncology, 27(24), 3929–3937.

    Article  PubMed  Google Scholar 

  35. Yao, H. Q., Peng, Y., Zhong, Z. Z., He, H. X., & Li, Z. H. (2004). Association of the expressions of platelet-derived growth factor receptor and c-Fos with the biological characteristics of bladder cancer. Di Yi Jun Yi Da Xue Xue Bao, 24(2), 177–179.

    CAS  PubMed  Google Scholar 

  36. Tiniakos, D. G., Mellon, K., Anderson, J. J., Robinson, M. C., Neal, D. E., & Horne, C. H. (1994). c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. British Journal of Urology, 74(6), 757–761.

    Article  CAS  PubMed  Google Scholar 

  37. Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S. C., Skinner, D. G., et al. (1995). Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. Journal of the National Cancer Institute, 87(21), 1603–1612.

    Article  CAS  PubMed  Google Scholar 

  38. Poon, E., Harris, A. L., & Ashcroft, M. (2009). Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine, 11, e26.

    Article  PubMed  Google Scholar 

  39. Theodoropoulos, V. E., Lazaris, A., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I., et al. (2004). Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. European Urology, 46(2), 200–208.

    Article  CAS  PubMed  Google Scholar 

  40. Theodoropoulos, V. E., Lazaris, A. C., Kastriotis, I., Spiliadi, C., Theodoropoulos, G. E., Tsoukala, V., et al. (2005). Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU International, 95(3), 425–431.

    Article  CAS  PubMed  Google Scholar 

  41. Palit, V., Phillips, R. M., Puri, R., Shah, T., & Bibby, M. C. (2005). Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncology Reports, 14(4), 909–913.

    CAS  PubMed  Google Scholar 

  42. Crew, J. P., O'Brien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D., et al. (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Research, 57(23), 5281–5285.

    CAS  PubMed  Google Scholar 

  43. Bernardini, S., Fauconnet, S., Chabannes, E., Henry, P. C., Adessi, G., & Bittard, H. (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. Journal of Urology, 166(4), 1275–1279.

    Article  CAS  PubMed  Google Scholar 

  44. Bochner, B. H., Esrig, D., Groshen, S., Dickinson, M., Weidner, N., Nichols, P. W., et al. (1997). Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clinical Cancer Research, 3(9), 1615–1622.

    CAS  PubMed  Google Scholar 

  45. Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Groshen, S., et al. (1997). Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. Journal of the National Cancer Institute, 89(3), 219–227.

    Article  CAS  PubMed  Google Scholar 

  46. Chatterjee, S. J., Datar, R., Youssefzadeh, D., George, B., Goebell, P. J., Stein, J. P., et al. (2004). Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Journal of Clinical Oncology, 22(6), 1007–1013.

    Article  CAS  PubMed  Google Scholar 

  47. Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G. E., Benedict, W. F., et al. (2004). p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. Journal of Clinical Oncology, 22(6), 1014–1024.

    Article  CAS  PubMed  Google Scholar 

  48. Shariat, S. F., Zlotta, A. R., Ashfaq, R., Sagalowsky, A. I., & Lotan, Y. (2007). Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Modern Pathology, 20(4), 445–459.

    Article  CAS  PubMed  Google Scholar 

  49. Shariat, S. F., Karakiewicz, P. I., Ashfaq, R., Lerner, S. P., Palapattu, G. S., Cote, R. J., et al. (2008). Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 112(2), 315–325.

    Article  PubMed  Google Scholar 

  50. Karam, J. A., Lotan, Y., Karakiewicz, P. I., Ashfaq, R., Sagalowsky, A. I., Roehrborn, C. G., et al. (2007). Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncology, 8(2), 128–136.

    Article  CAS  PubMed  Google Scholar 

  51. Birkhahn, M., Mitra, A. P., & Cote, R. J. (2007). Molecular markers for bladder cancer: the road to a multimarker approach. Expert Review of Anticancer Therapy, 7(12), 1717–1727.

    Article  CAS  PubMed  Google Scholar 

  52. Ørntoft, T. F., & Dyrskjøt, L. (2008). Gene signatures for risk-adapted treatment of bladder cancer. Scandinavian Journal of Urology and Nephrology Suppl, (218):166–174.

  53. Mitra, A. P., Lin, H., Cote, R. J., & Datar, R. H. (2005). Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. National Medical Journal of India, 18(6), 304–312.

    PubMed  Google Scholar 

  54. Rosser, C. J., Liu, L., Sun, Y., Villicana, P., McCullers, M., Porvasnik, S., et al. (2009). Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiology, Biomarkers and Prevention, 18(2), 444–453.

    Article  CAS  PubMed  Google Scholar 

  55. Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Li, W., Charytonowicz, E., Belbin, T. J., et al. (2003). Gene discovery in bladder cancer progression using cDNA microarrays. American Journal of Pathology, 163(2), 505–516.

    CAS  PubMed  Google Scholar 

  56. Modlich, O., Prisack, H. B., Pitschke, G., Ramp, U., Ackermann, R., Bojar, H., et al. (2004). Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clinical Cancer Research, 10(10), 3410–3421.

    Article  CAS  PubMed  Google Scholar 

  57. Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., et al. (2005). Bladder cancer outcome and subtype classification by gene expression. Clinical Cancer Research, 11(11), 4044–4055.

    Article  CAS  PubMed  Google Scholar 

  58. Dyrskjøt, L., Thykjaer, T., Kruhoffer, M., Jensen, J. L., Marcussen, N., Hamilton-Dutoit, S., et al. (2003). Identifying distinct classes of bladder carcinoma using microarrays. Nature Genetics, 33(1), 90–96.

    Article  PubMed  Google Scholar 

  59. Aaboe, M., Marcussen, N., Jensen, K. M., Thykjaer, T., Dyrskjøt, L., & Ørntoft, T. F. (2005). Gene expression profiling of noninvasive primary urothelial tumours using microarrays. British Journal of Cancer, 93(10), 1182–1190.

    Article  CAS  PubMed  Google Scholar 

  60. Dyrskjøt, L., Kruhoffer, M., Thykjaer, T., Marcussen, N., Jensen, J. L., Moller, K., et al. (2004). Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Research, 64(11), 4040–4048.

    Article  PubMed  Google Scholar 

  61. Dyrskjøt, L., Zieger, K., Real, F. X., Malats, N., Carrato, A., Hurst, C., et al. (2007). Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clinical Cancer Research, 13(12), 3545–3551.

    Article  PubMed  Google Scholar 

  62. Dyrskjøt, L., Zieger, K., Kruhoffer, M., Thykjaer, T., Jensen, J. L., Primdahl, H., et al. (2005). A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clinical Cancer Research, 11(11), 4029–4036.

    Article  PubMed  Google Scholar 

  63. Wild, P. J., Herr, A., Wissmann, C., Stoehr, R., Rosenthal, A., Zaak, D., et al. (2005). Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clinical Cancer Research, 11(12), 4415–4429.

    Article  CAS  PubMed  Google Scholar 

  64. Sanchez-Carbayo, M., Socci, N. D., Lozano, J., Saint, F., & Cordon-Cardo, C. (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. Journal of Clinical Oncology, 24(5), 778–789.

    Article  CAS  PubMed  Google Scholar 

  65. Schultz, I. J., Wester, K., Straatman, H., Kiemeney, L. A., Babjuk, M., Mares, J., et al. (2006). Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. International Journal of Cancer, 119(8), 1915–1919.

    Article  CAS  Google Scholar 

  66. Kuo, W. P., Jenssen, T. K., Butte, A. J., Ohno-Machado, L., & Kohane, I. S. (2002). Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics, 18(3), 405–412.

    Article  CAS  PubMed  Google Scholar 

  67. Zieger, K. (2008). High throughput molecular diagnostics in bladder cancer—on the brink of clinical utility. Molecular Oncology, 1(4), 384–394.

    Article  PubMed  Google Scholar 

  68. Ferre, F. (1992). Quantitative or semi-quantitative PCR: reality versus myth. PCR Methods and Applications, 2(1), 1–9.

    CAS  PubMed  Google Scholar 

  69. Schultz, I. J., Wester, K., Straatman, H., Kiemeney, L. A., Babjuk, M., Mares, J., et al. (2007). Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. European Urology, 51(2), 416–422.

    Article  CAS  PubMed  Google Scholar 

  70. Sanchez-Carbayo, M. (2003). Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clinical Chemistry, 49(1), 23–31.

    Article  CAS  PubMed  Google Scholar 

  71. Mitra, A. P., & Cote, R. J. (2007). Searching for novel therapeutics and targets: insights from clinical trials. Urological Oncology, 25(4), 341–343.

    CAS  Google Scholar 

  72. Youssef, R. F., Mitra, A. P., Bartsch, G., Jr., Jones, P. A., Skinner, D. G., & Cote, R. J. (2009). Molecular targets and targeted therapies in bladder cancer management. World Journal of Urology, 27(1), 9–20.

    Article  PubMed  Google Scholar 

  73. Takata, R., Katagiri, T., Kanehira, M., Tsunoda, T., Shuin, T., Miki, T., et al. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clinical Cancer Research, 11(7), 2625–2636.

    Article  CAS  PubMed  Google Scholar 

  74. Als, A. B., Dyrskjøt, L., von der Maase, H., Koed, K., Mansilla, F., Toldbod, H. E., et al. (2007). Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clinical Cancer Research, 13(15 Pt 1), 4407–4414.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 308, Los Angeles, CA, 90033, USA

    Anirban P. Mitra

  2. Department of Urology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 308, Los Angeles, CA, 90033, USA

    Claudia C. Bartsch

  3. Department of Urology, University of Ulm, Ulm, Germany

    Claudia C. Bartsch

  4. Department of Pathology, University of Miami Miller School of Medicine, 1611 NW 12th Avenue, Miami, FL, 33136, USA

    Richard J. Cote

Authors
  1. Anirban P. Mitra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia C. Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard J. Cote
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard J. Cote.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitra, A.P., Bartsch, C.C. & Cote, R.J. Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev 28, 317–326 (2009). https://doi.org/10.1007/s10555-009-9196-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-009-9196-5

Keywords

Search

Navigation